Advertisement

Topics

Ultragenyx’ Ace-ER fails in phase 3 GNE Myopathy trial

06:10 EDT 24 Aug 2017 | Pharmaceutical Business Review

Ultragenyx Pharmaceutical’s phase 3 study evaluating aceneuramic acid extended release (Ace-ER) in patients with GNE Myopathy (GNEM) failed to meet primary endpoint of showing a statistically significant difference in the upper extremity muscle strength composite score compared to placebo.

Original Article: Ultragenyx’ Ace-ER fails in phase 3 GNE Myopathy trial

NEXT ARTICLE

More From BioPortfolio on "Ultragenyx’ Ace-ER fails in phase 3 GNE Myopathy trial"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...